Investment Thesis
Quince Therapeutics is a pre-revenue biotech company burning $7.6M annually in operating cash flow with only ~2.4 years of cash runway remaining. The $35.9M net income appears driven by non-operating gains rather than core business operations, as evidenced by negative $14.6M operating income, creating a fundamental disconnect between reported earnings and operational reality.
Strengths
- Strong balance sheet with $18.2M cash against $26.6M total assets
- Zero long-term debt eliminates refinancing and solvency risk
- Solid liquidity metrics with 2.92x current ratio
Risks
- No revenue generation despite matured company status indicates failed commercialization or prolonged development stage
- Negative $7.6M annual operating cash burn with only 2-3 years of cash runway before capital requirements
- Operating income of -$14.6M versus net income of +$35.9M indicates non-operating gains masking operational losses and deteriorating EPS trends
- Zero insider Form 4 activity suggests lack of management confidence in fundamental business trajectory
Key Metrics to Watch
- Operating cash flow trend and projected runway before capital raise needed
- Revenue recognition timing and pipeline advancement status
- Cash burn rate relative to available liquidity
- Nature and sustainability of non-operating gains driving net income
Financial Metrics
Revenue
N/A
Net Income
35.9M
EPS (Diluted)
$2.88
Free Cash Flow
-7.6M
Total Assets
26.6M
Cash
18.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
229.1%
ROA
134.9%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.92x
Quick Ratio
2.92x
Debt/Equity
0.00x
Debt/Assets
41.1%
Interest Coverage
-15.25x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T09:02:25.853826 |
Data as of: 2026-03-31 |
Powered by Claude AI